Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights
$24,750.00   |  '

Congenital Heart Block – Executive Insights – Congenital Heart Block | Executive Insights | US/EU5 | 2022

Login to access report north_east
Buy report north_east

Congenital heart block (CHB), also known as atrioventricular block, is a rare heart block disorder in which maternal antibodies attack the impulse-generating heart muscles of fetuses and newborns. Minimizing the deterioration of heart muscles and preventing disease progression are the key treatment goals in CHB. No therapies are approved for CHB, and patients are managed with off-label drugs such as dexamethasone and IVIG, or through plasmapheresis and pacemaker implantation. In addition, no commercial pharmacotherapies are in the pipeline for CHB. A major unmet need is for effective therapies and represents a commercial opportunity for drug developers in this market.

QUESTIONS ANSWERED

  • What is the diagnosed incidence of CHB?
  • What is the current market landscape including the diagnostic and management practices
  • What are the current therapy and emerging therapy landscapes?
  • What is the estimated cost of treatment in different geographies?
  • What are the key unmet needs in the management of CHB?
  • What are the key market drivers and limiters?
  • What are the opinions of KOLs on different aspects of CHB?

PRODUCT DESCRIPTION

Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

GEOGRAPHY: United States, EU5

PRIMARY RESEARCH: 13 KOL interviews from November 2021 to January 2022

KEY DRUGS COVERED: Dexamethasone, intravenous immune globulin (IVIG)

Table of contents

Buy report north_east
Login to access report north_east

Related Market Assessment Reports

Report
Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)
Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids’ size. Progestins (e.g., norethindrone,…
north_east
Report
Thyroid Eye Disease – Executive Insights – Thyroid Eye Disease | Executive Insights (US)
north_east
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…
north_east
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, patients must…
north_east
Report
Amyotrophic Lateral Sclerosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east